# Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost–effectiveness analysis

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/lenvatinib-versus-sorafenib-for-unresectable-hepatocellular-carcinoma-a-cost/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Hongfu Cai,Longfeng Zhang,Na Li,Bin Zheng,Maobai Liu |
| Citations | 41 |
| DOI | 10.2217/cer-2020-0041 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W3028446962 |
| PMID | 32419473 |
| Type | article |
| Year | 2020 |

## Paper authors

- [Longfeng Zhang](https://scholariq.org/researchers/longfeng-zhang/)

## Paper journal

- [Journal of Comparative Effectiveness Research](https://scholariq.org/journals/journal-of-comparative-effectiveness-research/)

## Paper primary topic

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)

## Paper topics

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Hepatitis B Virus Studies](https://scholariq.org/topics/hepatitis-b-virus-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.